Andrew R. Haas, M.D., Ph.D.
Dr. Andrew Haas is a pulmonologist and Associate Professor of Medicine in Pulmonary, Allergy, and Critical Care Medicine at the Hospital of the University of Pennsylvania, as well as the Bronchoscopy Director and Director of the Interventional Pulmonary and Thoracic Oncology Program. His clinical expertise in interventional pulmonary and thoracic oncology has made him a leader in the care of patients with lung cancer and malignant pleural mesothelioma.[1]
Dr. Haas focuses on patients with benign and malignant pleural diseases and benign and malignant airway and parenchymal lung disorders. He performs advanced diagnostic procedures including intrathoracic lymphadenopathy, therapeutic bronchoscopy, and tumor debulking, as well as performing diagnostic procedures on patients with suspected malignant pleural conditions.[2]
Education and Career
Dr. Haas graduated from Villanova University with a Bachelor of Science in Biology and then earned his medical degree at the Jefferson Medical College of Thomas Jefferson University. While there, he also earned a Ph.D. in Chemistry and Molecular Biology. He then completed an internship and residency in Internal Medicine in the Department of Medicine of the Hospital of the University of Pennsylvania Philadelphia, as well as fellowships in Pulmonary, Allergy, and Critical Care Medicine and Interventional Pulmonary Training there. He also completed intensive training in rigid bronchoscopy in Marseille, France.[2]
Professional Activities and Memberships
Dr. Haas is actively involved in several professional associations, including:[1]
- American Association of Bronchology and Interventional Pulmonology, National
- American College of Chest Physicians, National
- American Thoracic Society, National
- Associate of Interventional Pulmonary Program Directors, National
- World Association for Bronchology, International
He also works closely with several industry partners on the development of new technology for patients with asthma and emphysema.
Research
Dr. Haas’ research interest is in early-phase novel immunotherapeutic clinical trials for patients with thoracic malignancies. He works closely with Drs. Steve Albelda and Carl June to translate pre-clinical animal model data into human clinical trials.[1]
His clinical trial work has included:[3]
Autologous Redirected RNA Meso-CIR T Cells
Start of enrollment: 2011 May 01
COMPLETED PHASE 1
Evaluation of the Spiration® Valve System for Emphysema to Improve Lung Function
Start of enrollment: 2013 Jun 01 COMPLETED
CART-meso in Mesothelin Expressing Cancers
Start of enrollment: 2014 Jun 01
COMPLETED PHASE 1
His recent publications include:[3]
Microbiome Profiling Demonstrates Concordance of Endotracheal Tube Aspirates With Direct Lower Airway Sampling in Intubated Patients. Graham-Wooten, J., Whiteside, S., Fitzgerald, A., Khatib, L., Bushman, F., Collman, R., McGinniss, J., Ma, K., DiBardino, D., Haas, A., Fuchs, B.>; Chest. 2024 Jan 9
Diagnostic yield of endobronchial ultrasound and virtual CT navigational bronchoscopy for biopsy of pulmonary nodules, mediastinal lymph nodes, and thoracic tumors in … Aoife Corcoran, Stephen Franklin, Erik Hysinger, Samuel Goldfarb, Pelton Phinizy, Jennifer Pogoriler, Sin Tran, David M DiBardino, Andrew R Haas, Joseph C Piccione>; Pediatric Pulmonology. 2024 Feb 1
Two cases of severe pulmonary toxicity from highly active mesothelin-directed CAR T cells. Andrew R Haas, Ryan J Golden, Leslie A Litzky, Boris Engels, Linlin Zhao, Fangmin Xu, John A Taraszka, Melissa Ramones, Brian Granda, Wan-Jung Chang, Julie Jadlowsky, …>; Molecular Therapy. 2023 Aug 2
